12月5日，百奥赛图-B(02315)盘中上涨5.54%，截至14:32，报6.1元/股，成交114.45万元。
百奥赛图(北京)医药科技股份有限公司是一家以创新技术驱动新药研发为主营业务的生物技术公司，拥有自主研发并拥有完全独立知识产权的全人抗体RenMiceTM平台，已建立起12项核心药物产品管线。公司正在对1000多个潜在可成药的靶点进行规模化药物开发，已签署了24项药物合作开发协议并与14家企业达成RenMice平台授权合作。
截至2024年中报，百奥赛图-B营业总收入4.1亿元、净利润-5067.3万元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.